View Filing Data

This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Mar. 31, 2012	Jun. 28, 2012
Document And Entity Information
Entity Registrant Name	VistaGen Therapeutics, Inc.
Entity Central Index Key	0001411685
Document Type	10-K
Document Period End Date	Mar. 31, 2012
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$ 22,210,726
Entity Common Stock, Shares Outstanding		17,559,963
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2012

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2012	Mar. 31, 2011
Current assets:
Cash and cash equivalents	$ 81,000	$ 139,300
Unbilled contract payments receivable	106,200	42,200
Prepaid expenses	50,900	23,300
Total current assets	238,100	204,800
Property and equipment, net	74,500	87,700
Security deposits and other assets	29,000	31,100
Total assets	341,600	323,600
Current liabilities:
Accounts payable	1,750,800	1,767,100
Accrued expenses	657,300	1,421,900
Notes payable and accrued interest	599,300	160,900
Notes payable and accrued interest to related parties	150,800	50,400
Put option and note term extension option liabilities		90,800
Capital lease obligations	10,500	30,100
Non-interest bearing promissory notes, net, including $525,000 to related parties		1,105,700
Deferred revenues	13,200	78,800
Convertible promissory notes, including $947,400 to related parties at March 31, 2011 - current portion		4,809,200
Accrued interest on convertible promissory notes		1,310,800
Total current liabilities.	3,181,900	10,825,700
Non-current liabilities:
Notes payable and accrued interest.	2,667,500	2,106,200
Notes payable and accrued interest to related parties.	125,100	210,800
Convertible promissory notes, net of current portion	700	3,326,000
Accrued interest on convertible promissory notes.	5,300	585,400
Accrued officers' compensation	57,000	57,000
Capital lease obligations.	9,700	4,500
Accounts payable.		1,140,600
Warrant liability		417,100
Total non-current liabilities	2,865,300	7,847,600
Total liabilities	6,047,200	18,673,300
Preferred stock, no par value; no shares authorized at March 31, 2012; 20,000,000 shares authorized at March 31, 2011; no shares issued and outstanding at March 31, 2012; 2,884,655 shares issued and outstanding at March 31, 2011		14,534,800
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2012; no shares authorized at March 31, 2011; 437,055 Series A shares issued and outstanding at March 31, 2012; no shares issued and outstanding at March 31, 2011	400
Common stock, $0.001 par value at March 31, 2012 and 2011; 200,000,000 and 400,000,000 shares authorized at March 31, 2012 and 2011, respectively; 18,704,267 and 5,241,110 shares issued at March 31, 2012 and 2011, respectively	18,700	5,200
Additional paid-in capital	52,539,500	9,867,400
Treasury stock, at cost, 2,083,858 shares of common stock held at March 31, 2012; no shares held at March 31, 2011	(3,231,700)
Notes receivable from sale of common stock to unrelated parties at March 31, 2012 and upon exercise of options and warrants by related parties at March 31, 2011	(250,000)	(184,100)
Deficit accumulated during development stage	(54,782,500)	(42,573,000)
Total stockholders' deficit	(5,705,600)	(32,884,500)
Total liabilities, preferred stock and stockholders' deficit	$ 341,600	$ 323,600

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2012	Mar. 31, 2011
Statement of Financial Position [Abstract]
Non-interest bearing promissory notes	$ 525,000
Convertible promissory notes		$ 947,400
Preferred Stock, No Par Value
Preferred Stock, Shares Authorized	0	20,000,000
Preferred Stock, Shares Issued		2,884,655
Preferred Stock, Shares Outstanding		2,884,655
Preferred Stock, per value	$ 0.001	$ 0.001
Preferred Stock, Authorized	$ 10,000,000	$ 0
PreferredStockSeriesASharesIssued	437,055	0
PreferredStockSeriesASharesOutstanding	$ 437,055	$ 0
Common Stock, Par Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	400,000,000
Common Stock, Shares, Issued	18,704,267	5,241,110
Common Stock, Shares, Outstanding
Treasury Stock, Shares	2,083,858	0

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended		166 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
Revenues:
Grant revenue	$ 1,342,200	$ 2,071,000	$ 12,762,700
Collaboration revenue			2,283,600
Other			1,123,500
Total revenues	1,342,200	2,071,000	16,169,800
Operating expenses:
Research and development	5,388,600	3,678,200	26,124,900
Acquired in-process research and development			7,523,200
General and administrative	4,997,000	4,957,700	27,118,400
Total operating expenses	10,385,600	8,635,900	60,766,500
Loss from operations	(9,043,400)	(6,564,900)	(44,596,700)
Other expenses, net:
Interest expense, net	(1,893,200)	(3,119,400)	(9,441,500)
Change in put and note extension option and warrant liabilities	(78,000)	203,900	418,500
Loss on early extinguishment of debt	(1,193,500)		(1,193,500)
Other income	200	(200)	47,500
Loss before income taxes	(12,207,900)	(9,480,600)	(54,765,700)
Income taxes	(1,600)	(1,600)	(16,800)
Net loss	$ (12,209,500)	$ (9,482,200)	$ (54,782,500)
Basic and diluted net loss per common share	$ (0.83)	$ (1.81)
Weighted average shares used in computing basic and diluted net loss per common share	14,736,651	5,241,110

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended		166 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
Cash flows from operating activities:
Net loss	$ (12,209,500)	$ (9,482,200)	$ (54,782,500)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	45,600	45,300	743,700
Amortization of discounts on 7%, 7.5% and 10% notes	57,200	71,000	259,200
Amortization of discounts on Platinum notes	909,000	1,376,600	3,548,700
Amortization of discounts on August 2010 short-term notes	14,300	557,700	572,000
Amortization of discounts on February 2012 12% convertible notes	(4,200)		(4,200)
Change in put and note term extension option and warrant liabilities	77,900	(203,900)	(418,600)
Fair value of Series C preferred stock, common stock, and warrants granted for services prior to the Merger	131,200		1,056,600
Stock-based compensation	1,591,300	1,628,800	4,354,300
Loss on early extinguishment of debt	1,193,500		1,193,500
Expense related to modification of warrants	741,700		741,700
Fair value of common stock granted for services following the Merger	452,000		452,000
Fair value of warrants granted for services following the Merger	564,500		564,500
Fair value of additional warrants granted under Discounted Warrant Exercise Program	138,100		138,100
Fair value of common stock issued for note term modification	22,400		22,400
Consulting services by related parties settled by issuing promissory notes			44,600
Acquired in-process research and development			7,523,200
Amortization of imputed discount on non-interest bearing notes			45,000
Gain on sale of assets			16,800
Changes in operating assets and liabilities:
Unbilled contract payments receivable	64,000	(205,000)	106,200
Prepaid expenses and other current assets	1,900	(630,900)	4,500
Security deposits and other assets	(2,100)	(4,500)	29,000
Accounts payable and accrued expenses	2,838,600	4,385,500	16,580,600
Deferred revenues.	(65,600)	(60,500)	13,200
Net cash used in operating activities	(3,565,800)	(841,300)	(17,508,500)
Cash flows from investing activities:
Purchases of equipment, net	(32,400)	(57,800)	(680,800)
Net cash used in investing activities	(32,400)	(57,800)	(680,800)
Cash flows from financing activities:
Net proceeds from issuance of common stock and warrants, including units	2,679,200		2,800,000
Proceeds from exercise of warrants under Discounted Warrant Exercise Program	1,166,300		1,166,300
Net proceeds from issuance of preferred stock and warrants			4,198,600
Proceeds from issuance of notes under line of credit			200,000
Proceeds from issuance of 7% note payable to founding stockholder			90,000
Net proceeds from issuance of 7% convertible notes			575,000
Net proceeds from issuance of 10% convertible notes and warrants			1,655,000
Net proceeds from issuance of Platinum notes and warrants			3,700,000
Net proceeds from issuance of 2008/2010 notes and warrants		270,000	2,971,800
Net proceeds from issuance of 2006/2007 notes and warrants			1,025,000
Proceeds from issuance of 7% notes payable			55,000
Net proceeds from issuance of August 2010 short-term notes and warrants		800,000	800,000
Net proceeds from issuance of February 2012 12% convertible notes and warrants	466,500		466,500
Repayment of capital lease obligations	(14,500)	(27,000)	(100,500)
Repayment of notes	(757,600)	(205,600)	(1,332,400)
Net cash provided by financing activities	3,539,900	837,400	18,270,300
Net increase in cash and cash equivalents	(58,300)	(61,700)	81,000
Cash and cash equivalents at beginning of period	139,300	201,000
Cash and cash equivalents at end of period	81,000	139,300	81,000
Supplemental disclosure of cash flow activities:
Cash paid for interest	265,400	147,400	439,700
Cash paid for income taxes	1,600	1,600	16,800
Supplemental disclosure of noncash activities:
Forgiveness of accrued compensation and accrued interest payable to officers transferred to equity			800,000
Exercise of warrants and options in exchange for debt cancellation			112,800
Settlement of accrued and prepaid interest by issuance of Series C Preferred Stock			35,300
Conversion of 10% notes payable, net of discount, and related accrued interest into Series C Preferred stock			2,050,300
Issuance of Series B-1 Preferred stock for acquired in-process research and development			7,523,200
Conversion of 7% notes payable, net of discount, and related accrued interest into Series B Preferred stock			508,000
Conversion of accounts payable into convertible promissory notes			893,700
Conversion of accounts payable into note payable		1,126,200	2,810,300
Conversion of accounts payable into common stock	275,400		1,824,100
Conversion of accrued interest on convertible promissory notes into common stock			921,400
Notes receivable from sale of common stock to related parties upon exercise of options and warrants			149,800
Capital lease obligations	19,000		139,700
Recognition of put option and note term extension option liabilities upon issuance of Platinum Notes			141,200
Incremental fair value of put option and note term extension option liabilities from debt modifications		158,000	479,400
Incremental fair value of note conversion option from debt modification		1,062,800	1,891,200
Incremental fair value of warrant from debt modifications		121,100	276,700
Recognition of warrant liability upon adoption of new accounting standard			151,300
Fair value of warrants issued with August 2010 short term notes		130,900	130,900
Note Discount upon issuance of August 2010 short-term notes		320,000	320,000
Fair value of warrants issued with February 2012 12% convertible notes	542,000		542,000
Note Discount upon issuance of February 2012 12% convertible notes	$ 495,200		$ 495,200

CONSOLIDATED STATEMENTS OF PREFERRED STOCK - USD ($)	12 Months Ended						22 Months Ended
CONSOLIDATED STATEMENTS OF PREFERRED STOCK - USD ($)	Mar. 31, 2012	Mar. 31, 2006	Mar. 31, 2005	Mar. 31, 2004	Mar. 31, 2002	Mar. 31, 2001	Mar. 31, 2000
Preferred Stock
Beginning Balance, Amount
Beginning Balance, Shares	2,884,655	2,694,575	2,304,248	947,498	748,212	429,350
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $24,000, Shares							429,350
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $5,500, Shares						2,580
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $39,800, Shares						316,282
Issuance of Series B preferred stock at $5.545 per share for cash, net of issuance costs of $97,200, Shares					199,286
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Shares				1,356,750
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $27,200, Shares			390,327
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount
Proceeds allocated to warrants issued in connection with Series C preferred stock, Shares
Issuance of Series C preferred stock at $6.00 per share for cash, net of issuance costs of $20,700, Shares		143,331
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Shares		46,749
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Shares	(2,884,655)
Ending Balance, Shares		2,884,655	2,694,575	2,304,248	947,498	748,212	429,350
Series A Preferred Stock
Beginning Balance, Amount	$ 964,700	$ 964,700	$ 964,700	$ 964,700	$ 964,700	$ 964,200
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $24,000, Amount							964,200
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $5,500, Amount						500
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $39,800, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, net of issuance costs of $97,200, Amount
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $27,200, Amount
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, net of issuance costs of $20,700, Amount
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(964,700)
Ending Balance, Amount		964,700	964,700	964,700	964,700	964,700	964,200
Series B Preferred Stock
Beginning Balance, Amount	2,651,100	2,651,100	2,651,100	2,651,100	1,643,300
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $24,000, Amount
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $5,500, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $39,800, Amount						1,643,300
Issuance of Series B preferred stock at $5.545 per share for cash, net of issuance costs of $97,200, Amount					1,007,800
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $27,200, Amount
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, net of issuance costs of $20,700, Amount
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(2,651,100)
Ending Balance, Amount		2,651,100	2,651,100	2,651,100	2,651,100	1,643,300
Series B-1 Preferred Stock
Beginning Balance, Amount	7,523,200	7,523,200	7,523,200
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $24,000, Amount
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $5,500, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $39,800, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, net of issuance costs of $97,200, Amount
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount				7,523,200
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $27,200, Amount
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount			(25,500)
Issuance of Series C preferred stock at $6.00 per share for cash, net of issuance costs of $20,700, Amount
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(7,523,200)
Ending Balance, Amount		7,523,200	7,523,200	7,523,200
Series C Preferred Stock
Beginning Balance, Amount	3,395,800	2,276,000
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $24,000, Amount
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $5,500, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $39,800, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, net of issuance costs of $97,200, Amount
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $27,200, Amount			2,301,500
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount			(25,500)
Issuance of Series C preferred stock at $6.00 per share for cash, net of issuance costs of $20,700, Amount		839,300
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount		280,500
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(3,395,800)
Ending Balance, Amount		3,395,800	2,276,000
Beginning Balance, Amount	14,534,800	13,415,000	11,139,000	3,615,800	2,608,000	964,200
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $24,000, Amount							964,200
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $5,500, Amount						500
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $39,800, Amount						1,643,300
Issuance of Series B preferred stock at $5.545 per share for cash, net of issuance costs of $97,200, Amount					1,007,800
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount				7,523,200
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $27,200, Amount			2,301,500
Issuance of Series C preferred stock at $6.00 per share for cash, net of issuance costs of $20,700, Amount		839,300
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount		280,500
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(14,534,800)
Ending Balance, Amount		$ 14,534,800	$ 13,415,000	$ 11,139,000	$ 3,615,800	$ 2,608,000	$ 964,200

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Series A Preferred Stock	Common Stock	Additional Paid-In Capital	Treasury Stock	Notes Receivable from Sale of Stock	Deficit accumulated during the development stage	Total
Beginning Balance, Amount at May. 25, 1998
Beginning Balance, Shares at May. 25, 1998
Initial sale of common stock for cash to Founder, Amount		$ 1,000	4,000				5,000
Initial sale of common stock for cash to Founder, Shares		1,000,000
Fair value of common stock issued for services, Amount		$ 400	400				400
Fair value of common stock issued for services, Shares		4,000
Effect of the Merger, Amount		$ 1,600	(1,600)
Effect of the Merger, Shares		1,569,000
Net Loss						(230,900)	(230,900)
Ending Balance, Amount at Mar. 31, 1999		$ 2,600	2,800			(230,900)	(225,500)
Ending Balance, Shares at Mar. 31, 1999		2,573,000
Beginning Balance, Amount at May. 25, 1998
Beginning Balance, Shares at May. 25, 1998
Net Loss							(54,782,500)
Ending Balance, Amount at Mar. 31, 2012	$ 400	$ 18,700	52,539,500	(3,231,700)	(250,000)	(54,782,500)	(5,705,600)
Ending Balance, Shares at Mar. 31, 2012	437,055	18,704,267
Beginning Balance, Amount at Mar. 31, 1999		$ 2,600	2,800			(230,900)	(225,500)
Beginning Balance, Shares at Mar. 31, 1999		2,573,000
Fair value of common stock issued for services, Amount		$ 100	21,800				21,900
Fair value of common stock issued for services, Shares		104,375
Sale of common stock for cash, Amount		$ 200	19,800				20,000
Sale of common stock for cash, Shares		200,000
Fair value of warrants issued for services			39,500				39,500
Net Loss						(700,000)	(700,000)
Ending Balance, Amount at Mar. 31, 2000		$ 2,900	83,900			(930,900)	(844,100)
Ending Balance, Shares at Mar. 31, 2000		2,877,375
Fair value of common stock issued for services, Amount		$ 100	32,900				33,000
Fair value of common stock issued for services, Shares		100,000
Fair value of warrants issued for services			13,100				13,100
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount			4,600				4,600
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		14,000
Proceeds allocated to warrants issued in connection with 7% convertible notes			91,200				91,200
Net Loss						(1,809,000)	(1,809,000)
Ending Balance, Amount at Mar. 31, 2001		$ 3,000	225,700			(2,739,900)	(2,511,200)
Ending Balance, Shares at Mar. 31, 2001		2,991,375
Fair value of warrants issued for services			33,100				33,100
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount			500				500
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		1,511
Proceeds allocated to warrants issued in connection with 10% convertible notes			7,300				7,300
Net Loss						(2,113,000)	(2,113,000)
Ending Balance, Amount at Mar. 31, 2002		$ 3,000	266,600			(4,852,900)	(4,583,300)
Ending Balance, Shares at Mar. 31, 2002		2,992,886
Fair value of warrants issued for services			46,500				46,500
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount		$ 0	5,000				5,000
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		15,000
Proceeds allocated to warrants issued in connection with 10% convertible notes			86,800				86,800
Net Loss						(502,600)	(502,600)
Ending Balance, Amount at Mar. 31, 2003		$ 3,000	404,900			(5,355,500)	(4,947,600)
Ending Balance, Shares at Mar. 31, 2003		3,007,886
Fair value of warrants issued for services			2,200				2,200
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount			600				600
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		2,925
Proceeds allocated to warrants issued in connection with 10% convertible notes			11,400				11,400
Net Loss						(8,755,500)	(8,755,500)
Ending Balance, Amount at Mar. 31, 2004		$ 3,000	419,100			(14,111,000)	(13,688,900)
Ending Balance, Shares at Mar. 31, 2004		3,010,811
Fair value of warrants issued for services			1,500				1,500
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount			4,800				4,800
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		10,708
Proceeds allocated to warrants issued in connection with Series C Preferred stock			25,500				25,500
Net Loss						(1,082,800)	(1,082,800)
Ending Balance, Amount at Mar. 31, 2005		$ 3,000	450,900			(15,193,800)	(14,739,900)
Ending Balance, Shares at Mar. 31, 2005		3,021,519
Fair value of warrants issued for services			3,300				3,300
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount			6,600				6,600
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		14,604
Net Loss						(1,772,100)	(1,772,100)
Ending Balance, Amount at Mar. 31, 2006		$ 3,000	460,800			(16,965,900)	(16,502,100)
Ending Balance, Shares at Mar. 31, 2006		3,036,123
Sale of common stock for cash, Amount			1,000				1,000
Sale of common stock for cash, Shares		10,000
Fair value of warrants issued for services			3,100				3,100
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Cash, Amount		$ 100	27,600				27,700
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Cash, Shares		33,465
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Debt cancellation, Amount		$ 100	112,700				112,800
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Debt cancellation, Shares		108,418
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Notes receivable, Amount		$ 200	149,600		(149,800)
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Notes receivable, Shares		204,498
Share-based compensation expense			109,800				109,800
Forgiveness of accrued compensation and accrued interest payable to officers			799,900				799,900
Net Loss						(1,999,800)	(1,999,800)
Ending Balance, Amount at Mar. 31, 2007		$ 3,400	1,664,500		(149,800)	(18,965,700)	(17,447,600)
Ending Balance, Shares at Mar. 31, 2007		3,392,504
Fair value of warrants issued for services			224,000				224,000
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount			1,900				1,900
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		2,234
Share-based compensation expense			247,600				247,600
Common stock issued upon settlement of employment contract, Amount			42,000				42,000
Common stock issued upon settlement of employment contract, Shares		20,000
Proceeds allocated to warrants issued in connection with Platinum Notes			221,000				221,000
Accrued interest on notes receivable					(9,200)		(9,200)
Net Loss						(5,446,700)	(5,446,700)
Ending Balance, Amount at Mar. 31, 2008		$ 3,400	2,401,000		(159,000)	(24,412,400)	(22,167,000)
Ending Balance, Shares at Mar. 31, 2008		3,414,738
Fair value of warrants issued for services			5,300				5,300
Share-based compensation expense			108,200				108,200
Accrued interest on notes receivable					(7,900)		(7,900)
Common stock issued upon exercise of options from 2008 Stock Incentive Plan and Scientific Advisory Plan, Amount			1,000				1,000
Common stock issued upon exercise of options from 2008 Stock Incentive Plan and Scientific Advisory Plan, Shares		3,500
Proceeds allocated to warrants issued in connection with Platinum Notes and incremental fair value of warrant modification			72,700				72,700
Effect of reverse stock split		$ (6)
Net Loss						(4,696,200)	(4,696,200)
Ending Balance, Amount at Mar. 31, 2009		$ 3,400	2,588,200		(166,900)	(29,108,600)	(26,683,900)
Ending Balance, Shares at Mar. 31, 2009		3,418,232
Share-based compensation expense			668,500				668,500
Accrued interest on notes receivable					(8,400)		(8,400)
Cumulative effect of adopting new accounting standard			(293,700)			142,300	(151,400)
Common stock issued upon exercise of warrant, Amount			100				100
Common stock issued upon exercise of warrant, Shares		1,086
Common stock issued for cancellation of accounts payable and accrued interest, Amount		$ 1,600	2,468,600				2,470,200
Common stock issued for cancellation of accounts payable and accrued interest, Shares		1,646,792
Incremental fair value of note conversion options from debt modification			828,500				828,500
Common stock issued for services, Amount		$ 200	262,300				262,500
Common stock issued for services, Shares		175,000
Fair value of warrants issued for services and incremental fair value of warrant modification			110,100				110,100
Fair value of warrants issued in connection with 7.5% Notes			291,200				291,200
Net Loss						(4,124,500)	(4,124,500)
Ending Balance, Amount at Mar. 31, 2010		$ 5,200	6,923,800		(175,300)	(33,090,800)	(26,337,100)
Ending Balance, Shares at Mar. 31, 2010		5,241,110
Share-based compensation expense			1,628,800				1,628,800
Accrued interest on notes receivable					(8,800)		(8,800)
Incremental fair value of note conversion options from debt modification			1,062,800				1,062,800
Fair value of warrants issued in connection with the August 2010 Short-Term Notes			252,000				252,000
Net Loss						(9,482,200)	(9,482,200)
Ending Balance, Amount at Mar. 31, 2011		$ 5,200	9,867,400		(184,100)	(42,573,000)	(32,884,500)
Ending Balance, Shares at Mar. 31, 2011		5,241,110
Fair value of warrants issued for services			564,500				564,500
Share-based compensation expense			1,591,300				1,591,300
Accrued interest on notes receivable						(1,000)	(1,000)
Reclassification of warrant liability to equity			424,100				424,100
Incremental value of Platinum note modification			1,070,600				1,070,600
Incremental value of Morrison Foerster warrant modification			58,700				58,700
Stock issued in May 2011 Private Placement, net of $202,000 placement fees, Amount		$ 2,200	3,674,000		(500,000)		3,176,200
Stock issued in May 2011 Private Placement, net of $202,000 placement fees, Shares		2,216,106
Payments on note receivable for sale of stock					250,000		250,000
Stock issued upon conversion of convertible promissory notes, Amount		$ 3,500	6,171,300				6,174,800
Stock issued upon conversion of convertible promissory notes, Shares		3,528,290
Stock issued upon conversion of all series of preferred stock, Amount		$ 2,900	14,531,900				14,534,800
Stock issued upon conversion of all series of preferred stock, Shares		2,884,655
Fair value of stock issued for services prior to the Merger, Amount		$ 1,400	2,224,100				2,225,500
Fair value of stock issued for services prior to the Merger, Shares		1,371,743
Forgiveness of notes at the Merger, Amount					185,100		185,100
Forgiveness of notes at the Merger, Shares
Stock issued upon exercise of modified warrants (includes Platinum exercises), Amount		$ 3,100	3,426,200				3,429,300
Stock issued upon exercise of modified warrants (includes Platinum exercises), Shares		3,121,259
Incremental value of warrant modifications (including modification of Platinum warrants)			1,028,900				1,028,900
Fair value of bonus warrants under Discounted Warrant Exercise Program			138,100				138,100
Stock issued in Fall 2011 Follow-on Offering, Amount		$ 100	111,200				111,300
Stock issued in Fall 2011 Follow-on Offering, Shares		63,570
Stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount		$ 100	102,100				102,200
Stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		113,979
Fair value of stock issued for services following the Merger, Amount		$ 200	451,800				452,000
Fair value of stock issued for services following the Merger, Shares		155,555
Placement fees on 12% Convertible Notes
Proceeds allocated to warrants issued and beneficial conversion feature in connection with 12% convertible notes			461,700				461,700
Stock issued in connection with note term extension, Amount			22,400				22,400
Stock issued in connection with note term extension, Shares		8,000
Stock issued upon conversion of Platinum Note to equity (net of Platinum warrant exercise reflected above), Amount	$ 200		3,387,700				3,387,900
Stock issued upon conversion of Platinum Note to equity (net of Platinum warrant exercise reflected above), Shares	231,090
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Amount			750,600	(750,600)
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Shares	45,980
Common stock exchanged for Series A Preferred under agreements with Platinum: Note and Warrant Exchange Agreement, Amount	$ 200		2,480,900	(2,481,100)
Common stock exchanged for Series A Preferred under agreements with Platinum: Note and Warrant Exchange Agreement, Shares	159,985
Net Loss						(12,209,500)	(12,209,500)
Ending Balance, Amount at Mar. 31, 2012	$ 400	$ 18,700	$ 52,539,500	$ (3,231,700)	$ (250,000)	$ (54,782,500)	$ (5,705,600)
Ending Balance, Shares at Mar. 31, 2012	437,055	18,704,267

Label	Element	Value
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	$ 14,534,800
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	14,534,800
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	14,534,800
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	14,534,800
Series B-1 Preferred Stock
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	7,523,200
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	7,523,200
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	7,523,200
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	$ 7,523,200
Preferred Stock
SharesIssuedForPreferredStock	vsta_SharesIssuedForPreferredStock	2,884,655
SharesIssuedForPreferredStock	vsta_SharesIssuedForPreferredStock	2,884,655
SharesIssuedForPreferredStock	vsta_SharesIssuedForPreferredStock	2,884,655
SharesIssuedForPreferredStock	vsta_SharesIssuedForPreferredStock	2,884,655
Series C Preferred Stock
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	$ 3,395,800
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	3,395,800
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	3,395,800
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	3,395,800
Series A Preferred Stock
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	964,700
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	964,700
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	964,700
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	964,700
Series B Preferred Stock
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	2,651,100
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	2,651,100
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	2,651,100
StockholdersEquityForPreferredStock	vsta_StockholdersEquityForPreferredStock	$ 2,651,100